Niaid DCR OCS-IRF, IRF airs translation of 89ZR-DF-ibalizumab
Active Awarded Last action
- Contract number
- 75N91022F00012
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,707,733
Award facts
- Contract value 100% obligated
- $3,707,733.00 Current and potential, with all options
- Completion date 59% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Other Administrative Action | $2,805,297 | |
| Other Administrative Action | $0 | |
| Original award | $902,436 |
About this award
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $3,707,733.00 Delivery Order contract is for the translation of 89Zr-DF-ibalizumab, which falls under NIAID's Division of Clinical Research (DCR) Operational Contracts and Services program. The contract has a period of performance through September 16, 2029 and utilizes a Cost Plus Fixed Fee pricing structure. No set-aside designation was used for this award. Leidos Biomedical Research Inc. is an established Federally Funded Research and Development Center (FFRDC) contractor for the National Cancer Institute (NCI), providing a range of biomedical research and facilities support services to federal agencies, particularly across NIH.
Quick answers
Who was awarded contract 75N91022F00012?
75N91022F00012 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 12, 2022.
How much is contract 75N91022F00012 worth?
The government has obligated $3,707,733 on 75N91022F00012.
Which agency awarded contract 75N91022F00012?
National Cancer Institute (National Institutes of Health) awarded 75N91022F00012, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91022F00012 an order under another contract?
Yes. 75N91022F00012 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00012 competed?
The extent of competition for 75N91022F00012 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award